Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Candesartan cilexetil is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension in adults and children 1 to < 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . Treatment of heart failure (NYHA class II-IV); FDA label
Also known as Candesartan (test), ATACAND
Candesartan · 7 trials · 7 indications
Change (reduction) in sitting DBP at the end of the study, when compared to sitting DBP at baseline.
Change (reduction) in sitting SBP at the end of the study, when compared to sitting SBP at baseline.
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments.
| Arm | Type | Description |
|---|---|---|
| 4 | NO_INTERVENTION | Placebo |
| 2 | ACTIVE_COMPARATOR | Candesartan cilexetil |
| 3 | ACTIVE_COMPARATOR | Hydrochlorothiazide (HCT) |
| 1 | EXPERIMENTAL | Candesartan cilexetil + Hydrochlorothiazide Combination |
| candesartan | EXPERIMENTAL | candesartan cilexetil 32 mg once daily |
| placebo | NO_INTERVENTION | control |
| 1 Candesartan | EXPERIMENTAL | - |
| 2 propranolol | ACTIVE_COMPARATOR | - |
| 3 Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Candesartan cilexetil | DRUG | 32 mg oral tablet |
| Hydrochlorothiazide | DRUG | 25 mg oral tablet |
| Candesartan/HCT 32/25 mg | DRUG | - |
| candesartan | DRUG | 32 mg oral tablet |
| Placebo | DRUG | - |
| propranolol | DRUG | Propranolol hydrochloride capsules 160 mg once daily, slow release formulation |
Inclusion Criteria: * Patients will be eligible for enrolment into the study (Visit 1) if they fulfil all of the following criteria: * Provision of signed Informed Consent * Primary hypertension, untreated or treated with a maximum of 2 antihypertensive drugs (substances), which the patient and the...
Candesartan is studied for congestive heart failure, hypertension, migraine without aura, type 1 diabetes, and type 2 diabetes. It has been evaluated in Phase 3 trials for congestive heart failure and in a Phase 2 trial for migraine prevention. It is an investigational small molecule developed by AstraZeneca PLC.
Candesartan targets AGTR1, the angiotensin II type 1 receptor, and acts as an antagonist. By blocking this receptor, it inhibits angiotensin II signaling. This mechanism underlies its evaluation in cardiovascular and metabolic conditions such as congestive heart failure, hypertension, and diabetes.
Candesartan is developed by AstraZeneca PLC, which trades under the ticker AZN. The company is responsible for its clinical development across the studied indications.
Candesartan is in Phase 3 development. It has completed Phase 3 trials in congestive heart failure and a Phase 2 trial in migraine prevention. It is investigational and has not been approved by the FDA for the indications studied.
Candesartan has been studied in completed trials including NCT00884663 (Phase 2, migraine prevention), NCT00634712 (Phase 3, CHARM Preserved), NCT00634400 (Phase 3, CHARM Alternative), and NCT00634309 (Phase 3, CHARM Added). These trials enrolled a total of 7,599 participants.